Regeneron's coming late to a group of drugs that's already...

Regeneron's coming late to a group of drugs that's already...

Regeneron's coming late to a group of drugs that's already worth billions - here's why the company thinks it can still compete The drug, cemiplimab, is a checkpoint inhibitor, a kind of drug that's part of a new class of cancer medications known as immunotherapy. There are already a handful of competitors that have gotten their versions of the drug approved, but t hat hasn't stopped Regeneron from pursuing it.

from Biotech News